Patents & Publications:

I. Patents

  • Reema Zeineldin. Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers. US Patent 9,532,949. Jan 3, 2017
  • Gabriel P Lopez, Reema Zeineldin, Menake E Piyasena, Sireesha Chemburu. Detection and delivery systems utilizing supported lipid bilayers.  US Patent 8,465,983. June 18, 2013
  • Gabriel P Lopez, Reema Zeineldin, Menake E Piyasena. Detection systems utilizing supported lipid bilayers (b). US Patent 8,334,107. Dec 18, 2012
  • Gabriel P Lopez, Reema Zeineldin, Menake E Piyasena. Detection systems utilizing supported lipid bilayers (a). US Patent 7,514,267. April 7, 2009

II. Blogs

III. Books

Reema Zeineldin. Ed. Cancer Nanotechnology. Methods in Molecular Biology. 2017; v.1530. Springer, New York, NY

IV. Book chapters

  • Zeineldin R. Nanotechnology for cancer screening and diagnosis: from innovations to clinical applications. In Kinam Park. Ed. Biomaterials for cancer therapeutics. 2nd Ed. 2020; p. 261-289. Elsevier, Cambridge, UK
  • Zeineldin R. Cancer nanotechnology: opportunities for prevention, diagnosis and therapy. In Reema Zeineldin. Ed. Cancer Nanotechnology. Methods in Molecular Biology. 2017; v. 1530, p.3-12. Springer, New York, NY
  • Zeineldin R. Nanotechnology for cancer diagnosis. In Kinam Park. Ed. Biomaterials for cancer therapeutics. 2013; p.137-164.  Woodhead Publishing Limited, Cambridge, UK.
  • Zeineldin, R. Carbon Nanotubes for Targeted Cancer Therapy. In Challa Kumar, Ed. of book series:  Carbon Nanomaterials for Life Sciences. 2011; p.349-380. Wiley-VCH, NJ.
  • Hudson LG, Zeineldin R, Silberberg M, Stack MS. Activated epidermal growth factor receptor in ovarian cancer. In Ovarian Cancer, 2nd Edition, Editors: M. Sharon Stack, David A. Fishman. Series: Cancer Treatment and Research 2009, 149:203-226, Springer.
  • Zeineldin R, Hudson LG. Epithelial cell migration in response to epidermal growth factor. In: Patel TB, and Bertics PJ, editors.  Epidermal growth factor, methods and protocols. Methods in Molecular Biology, 2006, v.327, p.147-158.  Humana Press, Totowa, NJ.

V. Journal articles

  • Youkhanna J, Syoufjy J, Rhorer M, Oladeinde O, Zeineldin R. Toward nanotechnology-based solutions for a particular disease: Ovarian cancer as an example. Nanotechnology Reviews 2013; 2(4):473-484.
  • Skandani AA, Zeineldin R, Al-Haik M. Effect of chirality and length on the penetrability of single-walled carbon nanotubes into lipid bilayer cell membranes. Langmuir 2012; 28(20):7872-7879.
  • Cowden Dahl K, Chan TW, Balkhi B, Zeineldin R. Management of Ovarian Cancer and Soft Tissue Sarcoma: focus on trabectedin. Clinical Medicine Reviews in Oncology. 2011, 3:93-105.
  • Kim PS; Djazayeri S; Zeineldin R. Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer. Gynecologic Oncology. 2011, 120:393-403.
  • Zeineldin R, Ning Y, Hudson LG. The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild type epidermal growth factor receptor and erbB2. Journal of Histochemistry & Cytochemistry. 2010. 58:529-541. Full text
  • Zeineldin R, Muller C, Stack MS, Hudson LG. Targeting the EGF receptor for ovarian cancer therapy. Journal of Oncology. Special Issue on “Epithelial Ovarian Cancer: Focus on Targeted Therapy”. 2010: 414676. Published online. Full text
  • Sireesha Chemburu, Kyle Fenton, Gabriel P Lopez, Zeineldin R. Biomimetic silica microspheres in biosensing. Molecules 2010, 15:1932-1957. Full text
  • Zeineldin R, Al-Haik M, Hudson LG. The role of polyethylene glycol integrity in specific receptor targeting of carbon nanotubes to cancer cells. Nano Letters 2009, 9(2):751-757.
  • Piyasena ME, Zeineldin R, Fenton K, Buranda T, and Lopez GP.  Biosensors based on release of compounds upon disruption of lipid bilayers supported on porous microspheres. Biointerphases 2008, 3(2): 38-49. Full text
  • Zeineldin R, Piyasena ME, Sklar LA, Whitten D, and Lopez GP. Detection of membrane biointeractions based on fluorescence superquenching.  Langmuir 2008, 24:4125-4131.
  • Hudson LG, Zeineldin R, Stack S. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clinical & Experimental Metastasis 2008, 25:643-655. Full text
  • Cowden Dahl KD, Zeineldin R, Hudson LG. PEA3 is necessary for epidermal growth factor receptor stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.  Molecular Cancer Research 2007, 5:413-421. Full text
  • Zeineldin R, Last JA, Slade A, Ista LK, Bisong P, O’Brien MJ, Brueck SRJ, Sasaki D, Lopez GP. Using bicellar mixtures to form supported and suspended lipid bilayers on silicon chips. Langmuir 2006, 22: 8163-8168.
  • Zeineldin R, Piasena ME, Troy S. Bergstedt, Larry A. Sklar, David Whitten, and Gabriel P. Lopez. Superquenching as a detector for microparticle-based flow cytometric assays. Cytometry A 2006, 69(5): 335-341. Full text
  • Zeineldin R, Rosenberg M, Ortega D, Buhr C, Chavez MK, Stack MS, Kusewitt DF, and Hudson LG, Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III.  Molecular Carcinogenesis 2006, 45(11):851-860.
  • Ning Y, Zeineldin R, Liu Y, Rosenberg M, Stack MS, and Hudson LG. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Research 2005, 65(20):9280-9286. Full text
  • Zeineldin R, Ekborg S, and Baker J. Oligomeric Forms of the 148 kDa cartilage matrix protein. Biochemical Journal 1997, 328(2): 665-668. Full text
  • Tas S, and Zein-El-Din RR. Automated Fructosamine assay with improved accuracy used to quantify nonenzymatic glycation of serum proteins in diabetes mellitus and chronic renal failure. Clinical Chemistry 1990, 36(10): 1825-1830.